Vanda Pharmaceuticals’ VGT-1849A gets orphan drug designation for polycythemia vera treatment
Vanda Pharmaceuticals Inc. has achieved a critical regulatory milestone with the U.S. Food and Drug Administration (FDA) granting orphan drug designation to its investigational therapy ... Read More
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two ... Read More